Redrow PLC
LSE:RDW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Redrow PLC
LSE:RDW
|
UK |
|
ARS Pharmaceuticals Inc
NASDAQ:SPRY
|
US |
|
A
|
Aileron Therapeutics Inc
NASDAQ:ALRN
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RDW's stock price target?
Not Available
RDW doesn't have any price targets made by Wall Street professionals.
What is Redrow PLC's Revenue forecast?
Projected CAGR
-3%
For the last 13 years the
compound annual growth rate for
Redrow PLC's revenue is
14%.
The projected
CAGR
for the next 3 years is
-3%.
What is Redrow PLC's Operating Income forecast?
Projected CAGR
-13%
For the last 13 years the
compound annual growth rate for
Redrow PLC's operating income is
30%.
The projected
CAGR
for the next 3 years is
-13%.
What is Redrow PLC's Net Income forecast?
Projected CAGR
-14%
For the last 13 years the
compound annual growth rate for
Redrow PLC's net income is
63%.
The projected
CAGR
for the next 3 years is
-14%.
